Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth
…
6,233€
-4,85%
Echtzeit-Aktienkurs Personalis Inc.
Bid:
Ask:
Nachrichten zur Personalis Inc. Aktie
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
…
Exciting Technology At Personalis, But Profitability Eludes Them
…
Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma
We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article,…
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
…
Global Gene Panel Market Size To Worth USD 4.46 Billion by 2033 | CAGR of 13.75%
The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript
…
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease.…
Personalis executive sells $1,297 in company stock By Investing.com
Personalis executive sells $1,297 in company stock…
Personalis Inc executive sells over $2,300 in stock By Investing.com
Personalis Inc executive sells over $2,300 in stock…
Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript
…
Needham raises Personalis stock target to $3.50, maintains buy rating By Investing.com
Needham raises Personalis stock target to $3.50, maintains buy rating…
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
…